|
|
|
Vol. 12, No. 21, pp. 3369-3381, November 1, 1998
1 Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego, La Jolla, California 92093-0636 USA; 2 Department of Immunology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030 USA; 3 Signal Pharmaceuticals, San Diego, California 92121 USA
| |
Abstract |
|---|
|
|
|---|
MAP kinase (MAPK) cascades are composed of a MAPK, MAPK kinase (MAPKK), and a MAPKK kinase (MAPKKK). Despite the existence of numerous components and ample opportunities for crosstalk, most MAPKs are specifically and distinctly activated. We investigated the basis for specific activation of the JNK subgroup of MAPKs. The specificity of JNK activation is determined by the MAPKK JNKK1, which interacts with the MAPKKK MEKK1 and JNK through its amino-terminal extension. Inactive JNKK1 mutants can disrupt JNK activation by MEKK1 or tumor necrosis factor (TNF) in intact cells only if they contain an intact amino-terminal extension. Mutations in this region interfere with the ability of JNKK1 to respond to TNF but do not affect its activation by physical stressors. As JNK and MEKK1 compete for binding to JNKK1 and activation of JNKK1 prevents its binding to MEKK1, activation of this module is likely to occur through sequential MEKK1:JNKK1 and JNKK1:JNK interactions. These results underscore a role for the amino-terminal extension of MAPKKs in determination of response specificity.
[Key Words: JNKK1; MEKK1; MAP kinase; interaction; specificity]
| |
Introduction |
|---|
|
|
|---|
MAP kinase (MAPK) cascades transduce extracellular cues to the
transcriptional machinery, thereby regulating gene expression, cellular
homeostasis, and differentiation (Cobb and Goldsmith 1995
; Herskowitz
1995
; Marshall 1995
). MAPK cascades or modules are
composed of a MAPK, a MAPK kinase (MAPKK or MEK), and a MAPKK kinase or
MEK kinase (MAPKKK or MEKK). The MAPKs mediate effector functions
through phosphorylation of substrates involved in cellular regulation
(Hill and Triesman 1995
; Karin and Hunter 1995
). The MAPKKKs, on the
other hand, receive regulatory inputs from cell-surface receptors. The
identification of multiple MAPKs, MAPKKs, and MAPKKKs, even in
unicellular eukaryotes, such as budding yeast, and the ability of these
kinases to phosphorylate and activate more than one target when tested
in vitro, pose a difficult question regarding the mechanisms that
confer biological specificity to MAPK signaling cascades. Despite the
potential for extensive cross talk, it is generally observed that
individual MAPKs are activated in response to distinct sets of stimuli.
Genetic analysis in yeast suggests at least two different solutions to
the specificity problem. The prototypical pheromone-responsive MAPK
cascade is organized as a distinct signaling module composed of the
MAPKs Fus3 and Kss1, the MAPKK Ste7, and the MAPKKK Ste11 (Herskowitz
1995
). This module is organized by the scaffolding protein Ste5, which
is believed to interact simultaneously with all three components (Choi
et al. 1994
; Marcus et al. 1994
; Printen and Sprague 1994
), as well as
with upstream regulators (Whiteway et al. 1995
). In addition, Ste5 acts
as an insulator, preventing cross talk between the pheromone responsive
module and other MAPK modules (Yashar et al. 1995
). Direct interactions
between STE7 and its targets Fus3 and Kss1, however, which are
independent of Ste5, were also detected (Choi et al. 1994
; Marcus et
al. 1994
; Printen and Sprague 1994
; Bardwell et al. 1996
). Ste11 and
Ste7 also regulate the invasive growth response, which is activated by
starvation (Roberts and Fink 1994
) and involves Kss1 but not Fus3,
which acts as the output kinase of the pheromone-responsive module
(Madhani et al. 1997
). It was postulated that the invasive growth MAPK
module is organized by another yet-to-be-identified scaffolding protein
analogous to Ste5 (Herskowitz 1995
). Another MAPK cascade of yeast
composed of MAPK Hog1, MAPKK Pbs2, and MAPKKKs Ssk2 and Ssk22, mediates osmoadaptation following activation of the osmosensor Sln1 (Brewster et
al. 1993
; Maeda et al. 1995
). Sho1, a second osmosensor with different
properties from Sln1, also regulates Pbs2 and Hog1 (Maeda et al. 1995
),
but in this case the signal is transmitted through the MAPKKK Ste11
(Posas and Saito 1997
). Therefore, Ste11 is involved in three distinct
MAPK modules activated by pheromones, starvation, or osmotic stress,
yet normally each of the MAPKs that it regulates is potently activated
only by one specific stimulus (Madhani et al. 1997
; Posas and Saito
1997
). Specificity could be maintained through three separate pools of
Ste11, but this remains to be demonstrated. It was proposed that
specificity in the Sho1 osmoresponsive MAPK module is maintained
through physical interactions between Pbs2, Hog1, and Ste11 (Posas and
Saito 1997
). Pbs2 also interacts with Sho1 (Posas and Saito 1997
), but
it remains to be determined whether Pbs2 interacts with all of these
proteins simultaneously.
By comparison, much less is known about the mechanisms that confer
specificity to MAPK modules in mammalian cells. The first mammalian
MAPK module defined is composed of the MAPKKK Raf-1 (c-Raf), the MAPKKs
MEK1/MEK2, and the MAPKs ERK1/ERK2 (Dent et al. 1992
; Cobb and Goldsmith 1995
; Marshall 1995
). A-Raf and B-Raf also
function as MAPKKKs capable of MEK and ERK activation (Marais et al.
1997
), although B-Raf is differentially regulated from c-Raf (Vossler
et al. 1997
). The first identified mammalian homolog of Ste11 was MEKK1
(Lange-Carter et al. 1993
). Recently, many related MAPKKKs, including
MEKK2, MEKK3, MEKK4, MEKK5, ASK, TAK, and MLK were identified
(Yamaguchi et al. 1995
; Blank et al. 1996
; Tibbles et al. 1996
; Wang et
al. 1996
; Gerwins et al. 1997
; Ichijo et al. 1997
). Initially, MEKK1
was proposed to be an activator of MEK1/MEK2
(Lange-Carter et al. 1993
). MEKK1, however, was found to activate
additional MAPKKs, including Jun amino (N)-terminal kinase kinase
1(MKK4) [JNKK1(MKK4)] (Dérijard et al. 1995
; Lin et al. 1995
),
JNKK2(MKK7) (Wu et al. 1997
), MKK3, and MKK6 (Stein et al. 1996
).
JNKK1(MKK4) activates both JNK and p38 MAPKs (Dérijard et al.
1995
; Lin et al. 1995
), whereas JNKK2(MKK7) is a specific JNK activator
(Holland et al. 1997
; Tournier et al. 1997
; Wu et al. 1997
) and MKK3
and MKK6 are specific p38 activators (Dérijard et al. 1995
;
Raingeaud et al. 1996
; Stein et al. 1996
). Therefore, MEKK1, and
probably other family members, such as MEKK2 and MEKK3 (Blank et al.
1996
), can potentially activate at least three MAPK modules. Controlled
expression of truncated MEKK1, however, results in much more efficient
activation of JNKs than ERKs (Minden et al. 1994
; Yan et al. 1994
).
Another similarity between MEKK1 and Ste11 is that once isolated from
the cell, both are constitutively active (Rhodes et al. 1990
; Neiman
and Herskowitz 1994
; Xu et al. 1996
). Therefore, it is essentially
impossible to biochemically demonstrate their activation by distinct
upstream inputs.
We investigated how MEKK1 can activate distinct MAPK modules. When expressed at low levels, MEKK1 is a highly efficient JNK activator and a somewhat less efficient p38 activator. Weak ERK activation is observed only on vast overexpression of MEKK1. The preference toward JNK (and p38) is attributable to a highly specific interaction between MEKK1 and JNKK1. None of the other MAPKKs can stably interact with MEKK1. The MEKK1:JNKK1 complex, however, is disrupted once JNKK1 is activated. JNKK1, on the other hand, can specifically interact with JNK and p38 but not with ERK. Competition experiments suggest that JNK (and p38) compete with MEKK1 for binding to JNKK1 and both interactions require the amino-terminal extension of JNKK1, which is not a part of its catalytic domain. These interactions are biologically relevant because inactive JNKK1 mutants can interfere with JNK activation in intact cells by certain upstream stimuli only if they contain an intact amino-terminal extension. Furthermore, mutations in the amino-terminal extension differentially affect the ability of JNKK1 to respond to upstream stimuli.
| |
Results |
|---|
|
|
|---|
Full-length and truncated MEKK1 preferentially activate JNK and p38
The ability of transiently expressed MEKK1 to activate MAPKs has
been studied mainly by expression of its catalytic domain (
MEKK1),
which at low expression levels activates the JNKs but not the ERKs
(Minden et al. 1994
; Yan et al. 1994
; Lin et al. 1995
). To determine
the specificity of native MEKK1, we isolated overlapping cDNAs
encompassing the entire open reading frame (ORF) of human MEKK1 (Y. Xia and B. Su, unpubl.; sequence available under GenBank accession no.
AF042838). Human MEKK1 is 83% identical to rat MEKK1 (Xu et al. 1996
)
and is composed of 1495 amino acids. We constructed a full-length (FL)
MEKK1 expression vector specifying a 200-kD polypeptide and several
proteolytic products (see Fig. 4A, below). We compared the ability of
this vector to activate JNK, p38, and ERK in mammalian cells with that
of a
MEKK1 vector. Increasing amounts of
MEKK1 or FL-MEKK1
were coexpressed transiently with a representative of each of the MAPK
subgroups (JNK1, p38
, or ERK2) tagged with an amino-terminal
hemagglutinin (HA) epitope. The MAPKs were isolated by
immunoprecipitation and their activities were determined by
immunecomplex kinase assays. Both
MEKK1 and FL-MEKK1 exhibited the
same selectivity in MAPK activation (Fig. 1). At low
inputs (10-100 ng of MEKK1 DNA), MEKK1 activated JNK1 very robustly
and p38
somewhat less efficiently. At these levels, MEKK1 had only
a marginal effect on ERK2 activity. Similar results were obtained in
HEK293 cells (data not shown). These results confirmed that MEKK1
preferentially activates JNK1 and to a lesser extent p38
, but is
ineffective in ERK2 activation. This selectivity is intrinsic to the
carboxy-terminal catalytic domain of MEKK1 and is not modified by its
amino-terminal extension. A lesser amount of the
MEKK1 expression
vector is needed to activate JNK or p38 than the FL-MEKK1 vector
because the catalytic domain is expressed more efficiently (data not shown).
|
MEKK1 preferentially activates JNKK1 in cells and in vitro
To identify which MAPKKs respond to MEKK1, vectors encoding
HA-tagged JNKK1 (Dérijard et al. 1995
; Lin et al. 1995
), MKK3 (Dérijard et al. 1995
), MKK6 (Raingeaud et al. 1996
; Stein et al.
1996
), MEK1, and MEK2 (Crews et al. 1992
) were coexpressed with
increasing amounts of
MEKK1. MAPKK activity was determined by
immunecomplex kinase assays. At low input (1 ng of
MEKK1 DNA or
less), MEKK1 exhibited strong preference for JNKK1 activation (Fig.
2A). Even JNKK2 was not effectively stimulated at
this input level (data not shown). At higher inputs (10-100 ng of
MEKK1 DNA), MEKK1 also activated the other MAPKKs, but JNKK1 was
still the most responsive (Fig. 2A). These results suggest that JNKK1 is most likely the preferred MAPKK target for MEKK1 in cells.
|
To examine further the specificity of MEKK1 activity, phosphorylation
of different MAPKKs was studied in vitro using recombinant purified
GST-tagged
MEKK1 as the kinase and purified glutathione S-transferase (GST)-MAPKK fusion proteins as substrates.
Despite the use of GST moieties on both the kinase and the substrate it is unlikely that these moieties greatly alter the interaction between
the two because they are engaged in formation of very stable homodimers
and cannot mediate heterotetramerization (Wallace et al. 1998
). Figure
2B shows that JNKK1 is the preferred substrate for MEKK1. The
Km value of the MEKK1-JNKK1 reaction is ~0.2
µM. Although the exact Km value may be
somewhat affected by the dimeric state of the enzyme and substrates
produced as GST fusion proteins, the specificity constant
(Vmax/Km) for JNKK1
phosphorylation is ninefold higher than the specificity constant for
JNKK2, the second-most efficient target for MEKK1. We also examined the
ability of MEKK1 to phosphorylate two JNKK1 deletion mutants lacking
its first 77 or 88 amino acids. Surprisingly, although the sites
phosphorylated by MEKK1 are within the catalytic domain of JNKK1
(Dérijard et al. 1995
; Lin et al. 1995
), these mutants,
JNKK1(78-399) and JNKK1(89-399), were poorly phosphorylated by MEKK1
(Fig. 2B). Although JNKK1(89-399) was devoid of kinase activity and
therefore may be improperly folded, JNKK1(78-399) is an active kinase
that responds to certain upstream stimuli (see Fig. 8, below).
MEKK1 directly and specifically interacts with JNKK1
In addition to conventional enzyme:substrate interactions,
components of signaling pathways tend to form stable complexes, whose
formation has an important role in determining specificity (Avruch et
al. 1994
; Bax and Jhoti 1995
; Cohen et al. 1995
; Kallunki et al. 1996
).
To explore whether such interactions determine the specificity of MEKK1
action, we performed coprecipitation experiments. Lysates of the
same cells in which we screened the response of MAPKKs to MEKK1
(Fig. 2A) were immunoprecipitated with anti-HA and coprecipitation
of MEKK1 was examined by immunoblotting. Only HA-JNKK1 formed a stable
complex with
MEKK1 (Fig. 3A, top panel). None of
the other MAPKKs, including MEK1, MEK2, MKK3, MKK6, and even JNKK2,
interacted with
MEKK1 under these conditions (Fig. 3A,C; data not
shown). The specificity of these interactions was further studied by
mixing cell lysates containing
MEKK1 with lysates containing each
of the HA-MAPKKs and a coprecipitation assay. Again, only JNKK1 formed
stable complexes with MEKK1 that could be precipitated by anti-HA (Fig.
3B). Similar specificity was exhibited by FL-MEKK1 and
immunoprecipitation of endogenous JNKK1 resulted in coprecipitation
of transiently expressed FL-MEKK1 (data not shown).
|
To investigate the specificity of MEKK1:JNKK1 interaction,
coprecipitation of other MAPKKKs, including Raf-1 (Dent et al. 1992
),
ASK (Ichijo et al. 1997
), NIK (Malinin et al. 1997
), and GCK (Pombo et
al. 1995
), with JNKK1 was examined. None of these MAPKKKs could be
coprecipitated with JNKK1 (Fig. 3D; data not shown). Raf-1 is the
MAPKKK for MEK1/MEK2 (Dent et al. 1992
). Correspondingly,
the catalytic domain of Raf-1 was efficiently coprecipitated with MEK2,
but not with JNKK1 (Fig. 3D). These data suggest that the specificity
of MEKK1 toward JNK and p38 is achieved through specific association
with JNKK1. Moreover, MAPKKK: MAPKK interactions may represent a
general mechanism for determining the specificity of MAPKKK action.
To define the part of JNKK1 that interacts with MEKK1, deletion mutants
of JNKK1 were constructed and expressed in Cos-1 cells as HA-tagged or
GST fusion proteins (Fig. 3E). Cell lysates containing different
HA-JNKK1 derivatives were mixed with cell lysates containing
MEKK1 and the mixtures were immunoprecipitated with HA antibodies. Coprecipitation of
MEKK1 was determined by immunoblotting. Only full-length JNKK1 stably interacted with
MEKK1 and the mere
deletion of only 45 amino acids from its amino-terminal extension was
sufficient to abolish this interaction (Fig. 3E). These results
together with the relative phosphorylation of the JNKK1 derivatives by MEKK1 (Fig. 2B; data not shown) indicate that an intact amino-terminal extension is required for a stable interaction between JNKK1 and MEKK1
and for efficient JNKK1 phosphorylation and activation. On its own,
however, the amino-terminal extension of JNKK1 is not sufficient for
stable binding to MEKK1 (Fig. 3E).
GST-MAPKK fusion proteins were expressed in Escherichia coli,
purified, and examined for their ability to precipitate
amino-terminally Express(Exp)-tagged FL-MEKK1 and its derivatives
from transfected cell extracts. Immunoblot analysis with anti-Express
detected a 200-kD FL-Exp-MEKK1 polypeptide and two carboxy-terminally
truncated forms (
C), 150 and 120 kD in size (Fig. 4A,
top). Only the 200-kD form, which contains an
intact carboxy-terminal kinase domain, interacted with GST-JNKK1. Very
little binding of this form to GST-JNKK2 or GST-MKK6 was observed. As
similar interactions were displayed by catalytically inactive MEKK1(KM)
mutant, MEKK1 kinase activity is not required for binding to JNKK1. An
antibody directed to the carboxy-terminal kinase domain of MEKK1
(anti-MEKK1) detected the full-length MEKK1 polypeptide and several
amino-terminally truncated forms (
N), the major one being 90 kD in
size (Fig. 4A, middle). Both this form and the full-length form were
precipitated by GST-JNKK1 but not by GST-JNKK2 or GST-MKK6. Although
the amino-terminal portion of MEKK1 is not necessary for binding to
JNKK1, it is likely to be involved in interactions with upstream
signaling proteins (Su et al. 1997
).
|
We also compared binding of either
MEKK1 expressed in Cos-1 cells
(mammalian
MEKK1) presented as a crude lysate or purified E. coli-expressed
MEKK1 (bacterial
MEKK1) to different
bacterially expressed and purified GST-MAPKK proteins (Fig. 4B). Only
JNKK1 was able to bind
MEKK1, regardless of its source. As this
interaction was exhibited between two purified, bacterially expressed
proteins, we conclude that JNKK1, but not other MAPKKs, binds directly
to the catalytic domain of MEKK1. Specific interaction between
MEKK1 and JNKK1 was also observed when E. coli-expressed
and purified GST-
MEKK1 were used to precipitate various
HA-MAPKKs expressed in Cos-1 cells (Fig. 4C).
JNKK1 phosphorylation disrupts its interaction with MEKK1
The effect of JNKK1 activation on its interaction with MEKK1 was
studied by comparing the binding of MEKK1 with wild-type JNKK1 and two
mutants
JNKK1(KR), which is defective in ATP binding and therefore
catalytically inactive, and JNKK1(AA), which can bind ATP but cannot be
activated by MEKK1 because it lacks the activating phosphoacceptor
sites (Lin et al. 1995
). In the absence of ATP or in the presence of
nonhydrolyzable ATP analog adenylyl-imidodiphosphate, tetralithium salt
(AMP-PNP), all three forms of JNKK1 bound MEKK1 equally well (Fig.
5). When ATP was included and the mixture was preincubated to allow phosphorylation of JNKK1 prior to the
precipitation precedure, however, wild-type JNKK1 and JNKK1(KR) bound
MEKK1 much less efficiently than JNKK1(AA). These results indicate that phosphorylation of JNKK1 by MEKK1 either weakens its association with
MEKK1 or promotes complete dissociation of the complex.
|
JNKK1 specifically interacts with JNK and p38, but not with ERK
We also examined the interaction of JNKK1 with various MAPKs.
Similar amounts of transiently expressed M2-tagged JNK1, ERK2, or
p38
were mixed with cell lysates containing GST-JNKK1 and the
mixtures were precipitated with glutathione-Sepharose (GSH). Immunoblotting revealed that GST-JNKK1 interacted stably with JNK1 and
p38
, but not with ERK2 (Fig. 6A). No
precipitation of any of the MAPKs occurred in the absence of
GST-JNKK1. In addition, transfected cell lysates containing
M2-JNK1 or M2-p38
were subjected to precipitation with GSH
beads after mixing with bacterially expressed GST fusion proteins
containing either FL-JNKK1, its catalytic domain JNKK1(89-399), its
amino-terminal extension JNKK1(1-87), or MKK6. JNK1 was precipitated
by GST-JNKK1 but not GST-JNKK1(89-399) or GST-MKK6 (Fig. 6B).
p38
, however, was precipitated by both GST-JNKK1 and GST-MKK6,
but not by GST-JNKK1(89-399). Interestingly, both JNK1 and p38
formed stable complexes with the amino-terminal extension of JNKK1,
JNKK1(1-87). More extensive deletion analysis revealed that removal of
only 43 amino acids from the amino terminus of JNKK1 abolished JNK or
p38
binding (Fig. 3E; data not shown). Therefore, in the case of
the JNKK1:JNK (or p38) interaction, the amino-terminal extension of
JNKK1 is necessary and sufficient.
|
JNKK1 also interacts with endogenous JNK. HEK293 cells were transfected with either GST-JNKK1 or GST-JNKK1(89-399) vectors and cell lysates were precipitated with GSH beads. Immunoblotting with anti-JNK1 revealed that GST-JNKK1, but not GST-JNKK1(89-399), interacts with endogenous JNK1 (Fig. 6C).
We examined the effect of JNKK1 phosphorylation on binding to JNK and
p38. GST-JNKK1, GST-JNKK1(KR), or GST-JNKK1(AA) were incubated with
MEKK1 in the absence or presence of ATP and examined for binding
to M2-JNK1 or M2-p38
by GST pull-down. Immunoblotting with
anti-M2 revealed that JNK1 or p38
interacted with phosphorylated JNKK1 somewhat less efficiently than with nonphosphorylated JNKK1 (Fig.
6D). Nevertheless, the effect of JNKK1 activation on binding to JNK or
p38 was far less dramatic than its disruptive effect on binding to
MEKK1 (cf. Figs. 6D and 5).
MEKK1 and JNK compete for binding to JNKK1
The amino-terminal extension of JNKK1 is required for binding to
either MEKK1 or to JNK and p38. We asked whether MEKK1, JNKK1, and JNK1
form a stable ternary complex. Fixed amounts of a cell lysate
containing GST-JNKK1 were mixed with a fixed amount of a
MEKK1
containing lysate and then increasing amounts of HA-JNK1 were added.
GST pull-down experiments revealed that as the amount of JNK1
increased, the amount of MEKK1 bound to JNKK1 decreased (Fig.
7A). Similar results were obtained when the amount of
HA-JNK1 incubated with GST-JNKK1 was fixed and increasing amounts of
MEKK1 were added (Fig. 7B). We also obtained similar results when
HA-p38
was used instead of HA-JNK1 (data not shown). As JNK does
not interact directly with MEKK1 (data not shown), these results
suggest that MEKK1 and JNK (or p38
) are unlikely to bind
simultaneously to JNKK1.
|
The amino-terminal extension of JNKK1 is required for inhibition of JNK activation and responsiveness to physiological activators
To examine the role of the amino-terminal extension of JNKK1 in
physiological signal transduction, we tested the ability of FL-JNKK1(AA) or its amino-terminally truncated derivatives thereof to
interfere with JNK activation in intact cells. Transient expression of
a small amount of
MEKK1 results in JNK activation, which is inhibitable by a FL(1-399) GST-JNKK1(AA) mutant (Fig.
8A). JNK activation, however, was not inhibited on
coexpression of equal amounts of amino-terminally truncated (78-399 or
89-399) GST-JNKK1(AA) mutants. These truncation mutants either failed
to respond or responded poorly to coexpression of MEKK1 (data not shown).
|
We also compared the ability of FL(1-399) and truncated (78-399)
GST-JNKK1 fusion proteins to respond to upstream stimuli. Whereas
the kinase activity of FL-GST-JNKK1 was stimulated by both sorbitol
and tumor necrosis factor (TNF), GST-JNKK1(78-399) was activated
by sorbitol but not TNF (Fig. 8B). The amino-terminal deletion also had
little effect on the responses to other stress stimuli
UV and
anisomycin (data not shown). The ability of inactivatable derivatives
of the two JNKK1 constructs, FL-GST-JNKK1(AA) and (78-399)
GST-JNKK1(AA), to interfere with JNK activation by upstream stimuli
was also examined (Fig. 8C). As described previously (Minden et al.
1995
), the activation of HA-JNK2 by TNF or epidermal growth factor
(EGF) was inhibited almost completely by coexpression of catalytically
inactive
MEKK1(KM). This mutant only partially inhibited the
responses to anisomycin or UV radiation. A similar inhibitory effect
was caused by coexpression of FL-GST-JNKK1(AA). Coexpression of a
similar amount of truncated (78-399) GST-JNKK1(AA), however, did not
significantly interfere with JNK activation by any of these stimuli.
| |
Discussion |
|---|
|
|
|---|
Eukaryotic cells use MAPK cascades to transfer information from
cell-surface receptors to transcription factors in the nucleus and
other important regulatory molecules (Herskowitz 1995
; Hill and
Triesman 1995
; Karin and Hunter 1995
; Marshall 1995
). The existence of
multiple MAPKs, MAPKKs, and MAPKKKs within a single cell raises an
important and not thoroughly explored problem regarding the specificity
of MAPK activation and action. We investigated how specific activation
of the JNK cascade is achieved. Although the MAPKKK MEKK1 was
originally identified as a MEK kinase (hence, the name MEKK) that
activates MEK1/MEK2 (Lange-Carter et al. 1993
; Xu et al.
1996
) (Fig. 2), when expressed at modest levels, MEKK1 does not cause
considerable ERK activation. Instead, it is a highly efficient
activator of the JNK cascade (Minden et al. 1994
; Yan et al. 1994
). By
comparing the ability of MEKK1 to activate various MAPKKs, we found
that JNKK1 is the preferred substrate for MEKK1. Similar results were
obtained in vitro and the specificity constant for JNKK1
phosphorylation by MEKK1 is at least 10-fold higher than the
specificity constant for any other MAPKK. The preferential phosphorylation and activation of JNKK1 by MEKK1 correlates with specific formation of MEKK1:JNKK1 complexes. None of the other mammalian MAPKKs that we examined can interact stably with MEKK1. This
specificity is underscored by the failure of JNKK2(MKK7), which is also
a JNK kinase (Holland et al. 1997
; Tournier et al. 1997
; Wu et al.
1997
), and MKK3 or MKK6, which are specific p38 kinases (Dérijard
et al. 1995
; Stein et al. 1996
), to interact with MEKK1. JNKK1 did not
bind to MAPKKKs other than MEKK1, including ASK, NIK, and Raf-1. We
did, however, detect stable interaction between Raf-1 and MEK2. The
stable interaction between MEKK1 and JNKK1 is functionally important
because it is abolished by short deletions removing the first 45 amino
acids of JNKK1, which also interfere with the phosphorylation of JNKK1
and its activation by MEKK1 or certain physiological stimuli, such as
TNF. These deletions, however, do not remove the phosphoacceptor sites
recognized by MEKK1, which are located within the catalytic domain of
JNKK1 (Lin et al. 1995
) and most importantly, do not abolish activation of JNKK1 by physical and chemical stresses. As purified recombinant MEKK1 and JNKK1 also form a stable complex, the interaction between the
two proteins is direct.
The requirement of the amino-terminal extension of JNKK1 for binding to MEKK1 strongly suggests that the complex between the two is not a standard enzyme:substrate complex formed by an interaction between the catalytic pocket of MEKK1 with the activation loop (which contains the phosphoacceptor sites) of JNKK1. In fact, substitution of the phosphoacceptor sites with nonphosphorylatable residues does not interfere with binding of JNKK1 to MEKK1 and catalytically inactive MEKK1 binds JNKK1 as efficiently as its wild-type counterpart. The MEKK1:JNKK1 complex is, however, highly sensitive to phosphorylation of JNKK1. Preincubation with ATP allowing phosphorylation of JNKK1 by MEKK1 prevents the coprecipitation of either wild-type or a catalytically inactive JNKK1 mutant, JNKK1(KR). ATP, however, has no effect on binding of a mutant that lacks the activating phosphoacceptor sites, JNKK1(AA), and therefore is not phosphorylated by MEKK1.
We also examined the direct interaction of JNK1 with MEKK1, as it was
reported previously that JNK and ERK interact with MEKK1 through the
amino-terminal extension of MEKK1 (Xu and Cobb 1997
). We found that
both JNK1 and ERK2 interacted weakly with FL-MEKK1, but not with
MEKK1 (data not shown). Similar weak interactions were also
observed between FL-MEKK1 and MKK6 (Fig. 4A). These interactions,
however, are much weaker than the interaction between FL-MEKK1 and
JNKK1 (Fig. 4A). We therefore conclude it is the MEKK1-JNKK1
interaction rather than the MEKK1-JNK interaction that determines the
specificity of this signaling cascade.
The interaction between MEKK1 and JNKK1 is only one component that
contributes to formation of a specific JNK MAPK module. We detected
stable JNKK1:JNK1 or JNKK1:p38
complexes but no JNKK1:ERK2 complexes. JNK1, on the other hand, interacted with JNKK1 but not with
MEK1/2 or MKK6, whereas p38
bound both JNKK1 and
MKK6. These interactions are consistent with the specificity of MAPK activation by MAPKKs, because JNKK1(MKK4) activates JNK and p38
(Dérijard et al. 1995
; Lin et al. 1995
), whereas MKK6 activates p38
but not JNK (Han et al. 1996
). These results are somewhat different from an earlier report that in mammalian cells JNKK1 could be
associated with JNK but not with p38
(Zanke et al. 1996
). Using
the more sensitive two hybrid system, however, the same authors found
that JNKK1 interacted equally well with JNK or p38
and that MKK6
interacts with p38
but not with JNK. The interaction between JNKK1
and p38
is likely to be physiologically relevant, because MEKK1 is
also an effective p38 activator (Fig. 1) and so far no major
differences in the response of JNK1/2 and p38
to
upstream stimuli were observed (Raingeaud et al. 1995
; T. Sudu and M. Karin, unpubl.).
The interaction with JNK1 or p38
also requires the amino-terminal
extension of JNKK1. In this case, however, amino-terminal extension is
sufficient for binding either JNK1 or p38
. Therefore, the
interaction with either JNK1 or p38
is also not a classical enzyme:substrate interaction. As both MEKK1 and JNK1 interact with the
amino-terminal extension of JNKK1, it is not surprising to find that,
at least in vitro, JNK1 and MEKK1 compete for binding to JNKK1 rather
than form a ternary complex. It is possible, however, that in the
presence of a scaffold protein such a complex does form. Unlike the
binding of JNKK1 to MEKK1, which is disrupted by JNKK1 activation, the
activation of JNKK1 has only a small effect on binding to JNK1. Based
on these results, we offer the simplified sequential interaction model
(Fig. 8D) to explain the organization and function of a specific MAPK
module consisting of JNK1, JNKK1, and MEKK1. According to this model,
active (or possibly inactive) MEKK1 binds JNKK1 in a manner that
depends on contacts with its amino-terminal extension. If MEKK1 is
active, JNKK1 is phosphorylated and the MEKK1:JNKK1 complex
dissociates. Activated JNKK1 is freed to specifically interact with its
substrate JNK1 (and p38
) through its amino-terminal extension.
Once this complex is formed, the MAPK is activated followed by somewhat slower dissociation of the JNKK1:JNK complex compared with the MEKK1:JNKK1 complex. The activated MAPK is then freed to phosphorylate downstream targets.
This model attributes a major role in determination of signaling specificity to the amino-terminal extension of JNKK1. The physiological role of this part of JNKK1 is demonstrated by several experiments. Short deletions that remove parts of the amino-terminal extension interfere with the ability of JNKK1 to be activated in response to TNF but have little effect on its response to physical and chemical stressors, such as sorbitol (osmotic shock) or UV radiation. Likewise, an intact amino-terminal extension is required for the ability of an inactivatable JNKK1 mutant to interfere with JNK activation by either TNF or EGF.
Is the model presented in Figure 8D consistent with other models
proposed to explain the organization of MAPK modules? An extensively
studied system is the pheromone-responsive MAPK cascade of yeast
(Herskowitz 1995
). In this case, functional integrity of the cascade
composed of Ste11, Ste7, and Fus3 depends on a fourth component, Ste5
(Choi et al. 1994
). Ste5 acts as a scaffold that can simultaneously
bind the three other components (Choi et al. 1994
; Marcus et al. 1994
;
Printen and Sprague 1994
). By doing so, Ste5 may facilitate information
transfer within the module while isolating it from inputs generated by
other MAPK modules, thereby preventing potential cross talk (Herskowitz
1995
; Levin and Errede 1995
). Ste7, however, can interact with Fus3 and
Kss1 in the absence of Ste5 and this interaction is also required for
optimal functioning of the pheromone-responsive module (Bardwell et al.
1996
). Interestingly, the interaction with Fus3 and Kss1 is mediated by
the amino-terminal extension of Ste7 (Bardwell et al. 1996
). Therefore,
a great deal of inherent specificity may exist between different
components of the pheromone-responsive module and one of the main roles
of Ste5 is to stabilize these interactions further and act as a
coactivator. Therefore, the most basic organization of the
pheromone-responsive MAPK module may not be all that different from
that of the JNK module. In addition, our results do not rule out the
existence of a scaffold protein that stabilizes the JNK module further.
A greater apparent similarity with the JNK module is, however,
exhibited by the osmosensitive Sho1-dependent MAPK module of yeast. In
that case, the MAPKK Pbs2 can interact stably with both the MAPK Hog1
and one of its MAPKKKs, which also happens to be Ste11 (Posas and Saito
1997
). It was not examined, however, whether the three kinases form a
ternary complex and the region of Pbs2 that mediates these interactions was not defined.
Formation of stable complexes that include all the components of a
given MAPK module, as proposed for the pheromone-responsive module
(Choi et al. 1994
; Herskowitz 1995
; Levin and Errede 1995
), creates a
conceptual problem as it prevents signal amplification. It was
hypothesized, however, that complexes between Ste5 and components of
the pheromone-responsive module are unstable and that the MAPKK and
MAPKs associate with Ste5 transiently (Choi et al. 1994
). It was even
proposed that Ste5 may facilitate the dissociation of the kinases,
thereby promoting signal amplification (Elion et al. 1995
). On the
other hand, stable complexes could be needed to restrict the action of
kinases, such as Ste11, which is involved in three different and
distinctly regulated MAPK cascades.
Although stable and specific MAPKKK:MAPKK interactions have not been
amply described, we find that in addition to the specific MEKK1:JNKK1
interaction, Raf-1 interacts with its target MEK2 but not with JNKK1.
This interaction could be mediated by a proline-rich sequence unique to
MEK1/2 and is inserted into their kinase domain (Catling
et al. 1995
). Several stable and specific MAPKK:MAPK interactions, on
the other hand, have been documented. In addition to JNKK1:JNK1,
JNKK1:p38
and Ste7:Fus3 complexes, MEK:ERK complexes were also
described (Fukuda et al. 1997
). In this case, the interaction is also
mediated by the amino-terminal extension of the MAPKK. Despite the
absence of obvious primary sequence homology between the amino-terminal
extensions of JNKK1, Ste7, and MEK, the three regions appear to serve
the same function. In the future, it would be of interest to determine
the structure of these regions and identify the basis for their
specific interactions with the corresponding MAPKs and MAPKKKs.
| |
Materials and methods |
|---|
|
|
|---|
Reagents, antibodies, cells, and plasmids
Phorbol-12-myristate 13-acetate (TPA), anisomycin, sorbitol, ATP, and protein A-agarose were from Sigma, AMP-PNP and EGF were from Calbiochem, and TNF was a gift from Chiron. Glutathione (GSH)-Sepharose 4B was purchased from Pharmacia. Anti-HA was purified from ascites fluid of mice bearing hybridoma 12CA5; anti-M2 was from Kodak; anti-MEKK1 (C22), anti-Raf1 (C12), and anti-Express were from Santa Cruz Antibodies; anti-phospho JNKK1 was from Boehringer Mannheim; monoclonal anti-JNK1 (333.8) was from Pharmingen; and anti-GST was a gift from Dr. Ebrahim Zandi (UCSD). HEK293, Cos-1, and HeLa cells were grown in Dulbecco's modified Eagle (DME)-high glucose medium with 10% fetal calf serum, 1% glutamine, and 1% penicillin and streptomycin (GIBCO).
The different plasmids were either described previously (Minden et al.
1994
, 1995
; Cavigelli et al. 1995
; Lin et al. 1995
; Wu et al. 1997
) or
constructed by standard recombinant DNA procedures (details available
on request). MEKK1 4.7-kb cDNA was isolated from HeLa, B-cell, and
Jurkat cDNA libraries. This cDNA was subcloned into pCDNA3.1
(Invitrogene Inc.) in-frame with the Express epitope sequence. The
ATP-binding site mutant MEKK1 [MEKK1(K1255M)] was constructed using
Chameleon double-stranded, site-directed mutagenesis kit (Stratagene).
Plasmid DNAs were introduced into mammalian cells using Lipofectamine as suggested by the manufacturer (GIBCO).
Proteins
GST fusion proteins were expressed and purified on GSH-Sepharose
(Hibi et al. 1993
). GST-
MEKK1 contains human MEKK1(1199-1496) in-frame with GST at its amino terminus. The His6-
MEKK1
protein contains carboxy-terminal 385 amino acids of human MEKK1 in
pRSET (Invitrogene, Inc.) in-frame with the (His)6 tag.
Cell lysates were prepared 40-48 hr after transfection in lysis buffer [50 mM Tris-HCl (pH 7.6), 250 mM NaCl, 1% Triton X-100, 0.5% NP-40, 3 mM EGTA, 3 mM EDTA, 100 µM Na3VO4, 10% glycerol] for immunecomplex kinase assays or in low salt lysis buffer [50 mM HEPES (pH 7.6), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100, 10% glycerol] for coprecipitation and GST pull-down assays.
Coprecipitation and GST pull-down assays
For coprecipitation assays, mixtures of cell lysates and proteins were precleared by incubation with protein A-agarose at 4°C for 30 min using washing buffer [20 mM HEPES (pH 7.6), 150 mM NaCl, 0.1% Triton X-100, 10% glycerol]. The lysates were then immunoprecipitated with appropriate antibodies and protein A-agarose at 4°C for 2 hr. The beads were then washed six times with washing buffer and the precipitates eluted with sample buffer and resolved by SDS-PAGE. After electrophoresis, proteins were transferred onto Immobilon membrane and detected by immunoblotting with appropriate antibodies and enhanced chemiluminescence (ECL; Amersham). GST pull-down assays were done in a similar manner except that GSH-Sepharose beads were used instead of protein A-agarose and antibodies.
Protein kinase assays
Immunecomplex kinase assays were performed as described (Minden et
al. 1994
). The kinetics of MAPKK phosphorylation by
MEKK1 were
determined by quantifying the amount of 32P incorporation
into purified substrates in a discontinuous assay. MEKK1 was
preincubated with unlabeled ATP for 30 min, followed by the addition of
[
-32P]ATP (5 µCi/reaction) and
GST-MAPKK substrates. Reactions were carried out in 96-well plates for
1 hr at room temperature and terminated by addition of trichloroacetic
acid (TCA). The TCA precipitates were collected on 96-well glass-fiber
plates (Packard) and analyzed for their 32P content using a
Packard TopCount scintillation counter. Data were corrected for MAPKK
and
MEKK1 autophosphorylation. To obtain kinetic constants, the
data were fit to the Michaelis-Menten equation with a nonlinear least
squares method.
| |
Acknowledgments |
|---|
We thank J. Han, Z. Liu, and N. Li for providing expression vectors; E. Zandi for MEKK1 protein and helpful discussions; and B. Errede and T. Hunter for critical comments. We also thank O. Chen for technical assistance and B. Thompson for manuscript preparation. Y.X. and Z.W. were supported by postdoctoral fellowships from the Irvington Research Institute and Human Frontier Science Project Organization (HFSPO). Research was supported by HFSPO grant RG-598/96M and National Institutes of Health grant HL 35018.
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked `advertisement' in accordance with 18 USC section 1734 solely to indicate this fact.
| |
Footnotes |
|---|
Received July 6, 1998; revised version accepted September 4, 1998.
4 Corresponding author.
E-MAIL karinoffice{at}ucsd.edu; FAX (619) 534-8158.
| |
References |
|---|
|
|
|---|